Abbott Laboratories ABT
US equityMarket cap rank #93Medical DevicesBrain-Computer InterfaceInfectious DiseaseMpox (monkeypox)
$109.93 −$3.67 (-3.23%)
Market closed · Nov 6, 8:20 pm ET · Last extended-hours $109.93 0.00%
Open$111.08
Prev close$113.60
Day range$109.81 – $111.81
Volume8.35M
Market cap$190.39B
P/E (TTM)40.9
Dividend yield2.26%
Earnings
Average move on report day±4.5%last 16 reports
Closed higher7 of 1644% of the time
Best reaction+10.7%
Worst reaction-10.0%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 21 Oct 2026 | Pre Market | ±5.7% | -1.89% | Within range |
| 2026/Q2 | 16 Jul 2026 | Pre Market | ±4.6% | +10.71% | Bigger than priced |
| 2026/Q1 | 16 Apr 2026 | Pre Market | ±4.6% | -6.00% | Bigger than priced |
| 2025/Q4 | 22 Jan 2026 | Pre Market | ±3.4% | -10.04% | Bigger than priced |
| 2025/Q3 | 15 Oct 2025 | Pre Market | ±3.5% | -2.43% | Within range |
| 2025/Q2 | 17 Jul 2025 | Pre Market | ±3.6% | -8.52% | Bigger than priced |
| 2025/Q1 | 16 Apr 2025 | Pre Market | ±3.8% | +2.76% | Within range |
| 2024/Q4 | 22 Jan 2025 | Pre Market | ±3.5% | +0.85% | Within range |
| 2024/Q3 | 16 Oct 2024 | Pre Market | ±3.7% | +1.53% | Within range |
| 2024/Q2 | 18 Jul 2024 | Pre Market | ±4.5% | -4.40% | Within range |
| 2024/Q1 | 17 Apr 2024 | Pre Market | ±4.2% | -3.03% | Within range |
| 2023/Q4 | 24 Jan 2024 | Pre Market | ±3.2% | -2.83% | Within range |
| 2023/Q3 | 18 Oct 2023 | Pre Market | ±4.4% | +3.71% | Within range |
| 2023/Q2 | 20 Jul 2023 | Pre Market | ±3.8% | +4.24% | Bigger than priced |
| 2023/Q1 | 19 Apr 2023 | Pre Market | ±3.2% | +7.82% | Bigger than priced |
| 2022/Q4 | 25 Jan 2023 | Pre Market | ±3.5% | -1.36% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Where the revenue comes from
Quarter 2026/Q2
By business line
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$13.01B+14.5% YoY
Operating profit$1.36B-34.0% YoY
Net profit$920.00M-44.0% YoY
Diluted EPS$0.53-43.6% YoY
Free cash flow$1.99B+28.9% YoY
Operating cash flow$2.49B
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin56.9%
Operating margin13.8%
Net margin9.7%
Liabilities / assets52.6%
Cash & investments$5.60B
Total debt$32.61B
Net cash (debt)-$27.01B
No comments yet — be the first to weigh in on ABT.
Sign in to join the discussion.